CN114452274A - Application of plateau catechuic acid in preparing medicine for treating polycystic ovary syndrome - Google Patents
Application of plateau catechuic acid in preparing medicine for treating polycystic ovary syndrome Download PDFInfo
- Publication number
- CN114452274A CN114452274A CN202210076827.5A CN202210076827A CN114452274A CN 114452274 A CN114452274 A CN 114452274A CN 202210076827 A CN202210076827 A CN 202210076827A CN 114452274 A CN114452274 A CN 114452274A
- Authority
- CN
- China
- Prior art keywords
- plateau
- ovary syndrome
- polycystic ovary
- catechin
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 79
- 239000003814 drug Substances 0.000 title claims abstract description 42
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 title claims abstract description 33
- 229950001002 cianidanol Drugs 0.000 title claims abstract description 33
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 40
- 235000005487 catechin Nutrition 0.000 claims abstract description 40
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 210000001672 ovary Anatomy 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 239000003098 androgen Substances 0.000 claims abstract description 13
- 210000004246 corpus luteum Anatomy 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims abstract description 10
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000011957 flavonols Nutrition 0.000 claims abstract description 7
- 229930000044 secondary metabolite Natural products 0.000 claims abstract description 7
- 239000000178 monomer Substances 0.000 claims abstract description 5
- 150000002216 flavonol derivatives Chemical class 0.000 claims abstract description 4
- 230000002357 endometrial effect Effects 0.000 claims description 13
- 210000002966 serum Anatomy 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 150000001765 catechin Chemical class 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000027758 ovulation cycle Effects 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000000451 tissue damage Effects 0.000 claims description 4
- 231100000827 tissue damage Toxicity 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims 4
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 22
- 230000012173 estrus Effects 0.000 abstract description 20
- 206010036049 Polycystic ovaries Diseases 0.000 abstract description 9
- 230000008859 change Effects 0.000 abstract description 7
- 238000010172 mouse model Methods 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 210000004696 endometrium Anatomy 0.000 abstract description 5
- 239000003651 drinking water Substances 0.000 abstract description 3
- 235000020188 drinking water Nutrition 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000463 material Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002611 ovarian Effects 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003756 cervix mucus Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 150000007946 flavonol Chemical class 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000031877 prophase Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 244000239659 Eucalyptus pulverulenta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000283089 Perissodactyla Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of plateau catechin (3,4-dihydroxyphenyl acetic acid, DOPAC) in preparing a medicament for treating polycystic ovary syndrome. The medicament in the application is plateau catechin, belongs to a secondary metabolite monomer of flavonols, has the medicament preparation concentration of 80 mu mol/L, and is dissolved in drinking water, and DOPAC is proved at an animal level to improve the symptoms of polycystic ovary syndrome (PCOS) model mice: improving the polycystic change of ovaries of PCOS model mice, and increasing the quantity of corpus luteum in the ovaries; improving the endometrium; improving the disturbance of the estrus cycle of a PCOS model mouse; reduce androgen levels in PCOS model mice. At present, polycystic ovarian syndrome lacks of treatment medicines aiming at causes, and plateau catechin has a treatment effect on polycystic ovarian syndrome model mice and can be used for preparing medicines for treating polycystic ovarian syndrome.
Description
Technical Field
The invention relates to a medical product containing organic effective components, in particular to application of plateau catechin in preparing a medicine for treating polycystic ovary syndrome.
Background
Polycystic ovary syndrome (PCOS) is a gynecological disease with rare or no ovulation, abnormally elevated androgen levels, and polycystic ovarian changes. The main symptoms of the patients are obesity and insulin resistance caused by metabolic dysfunction; hirsutism, infertility, and acne caused by hormone secretion disorder. In addition, patients with polycystic ovarian syndrome are at higher risk for endometrial and ovarian cancer. The prevalence rate of polycystic ovarian syndrome is close to 10% at present, but the pathogenesis of polycystic ovarian syndrome is still unclear. Clinically, the treatment is mainly guided by a life style, is assisted by an oral contraceptive to regulate the menstrual cycle, or is carried out by a mode of regulating the metabolic function of a patient by metformin, and has an unobjective curative effect by a treatment means directly aiming at hormone secretion, for example, gonadotropin releasing hormone and a medicament simulating the effect of the gonadotropin releasing hormone have great side effect on the patient, and due to the particularity of hormone medicaments, high requirements are provided for the medication of a clinician, so that great difficulty is brought to the treatment. In recent years, in the search for the cause and treatment of polycystic ovary syndrome, researchers have considered intestinal flora as one of the causes of polycystic ovary syndrome, and have made some progress in the study of intestinal flora and its metabolites for the treatment of polycystic ovary syndrome. In this patent we claim the role of the monomeric plateau catechin, a flavonol secondary metabolite, in the treatment of polycystic ovary syndrome.
Plateau catechin (DOPAC) is white to off-white powder, is easily soluble in water and methanol, and has molecular formula C8H8O4. Plateau catechins are catechols, a secondary metabolite of flavonols, also known as 3, 4-dihydroxybenzeneacetic acid, and a metabolite of the neurotransmitter dopamine. Plateau catechins are widely present in a variety of plants, including olives, alfalfa, caraway, etc., and can be extracted from natural plants or synthesized artificially.
Disclosure of Invention
Plateau catechins have various biological functions, such as anti-inflammatory, antioxidant, antiviral, protective effects against apoptosis, mitochondrial dysfunction, and the like. Research shows that the antioxidation of the plateau catechin has certain inhibition effect on proliferation and transfer of gastric cancer cells and colon cancer cells. Further studies have shown that plateau catechins have therapeutic effects on hypertension and acute liver failure. However, no clear report is made on the treatment effect of the plateau catechin in the polycystic ovary syndrome at present, and the invention explores the effect of the plateau catechin in the treatment of the polycystic ovary syndrome.
The invention aims to solve the technical problem of new medical application of plateau catechin.
The invention provides an application of plateau catechin in preparing a medicament for treating polycystic ovary syndrome.
In a second aspect, the invention provides a medicament for treating polycystic ovary syndrome, which comprises plateau catechin.
In a third aspect, the invention provides the use of plateau catechins in the manufacture of a product comprising any one or more of the following effects: (1) increasing the number of corpus luteum in the ovary of the subject; (2) treating endometrial tissue damage; (3) relieving the disturbance of the estrous cycle of the affected subject; (4) reducing serum androgen levels in the subject.
The invention has the beneficial effects that:
the invention finds the new application of the plateau catechin and expands the application range of the plateau catechin. The invention discovers that plateau catechin can relieve the disease symptoms of a polycystic ovary syndrome model mouse, improve the hormone disorder of the polycystic ovary syndrome model mouse and improve the ovarian lesion of the polycystic ovary syndrome model mouse. At present, polycystic ovarian syndrome lacks of treatment medicines aiming at causes, and plateau catechin has a treatment effect on polycystic ovarian syndrome model mice and can be used for preparing medicines for treating polycystic ovarian syndrome.
Drawings
FIG. 1 is a graph of the result of plateau catechin improving PCOS model mouse ovarian polycystic transformation, hematoxylin-eosin (HE) staining chart, and the scale is 400 μm. A-C are normal mouse ovaries, D-F are PCOS model mouse ovaries, and G-I are plateau catechol treated mouse ovaries.
FIG. 2 is a graph of the result of improvement of PCOS model mouse endometrium morphology by plateau catechol, and a hematoxylin-eosin (HE) staining graph with a scale of 400 μm. A is normal mouse ovary, B is PCOS model mouse ovary, C is plateau catechol treated mouse ovary, and D is statistical chart of intraovarian dilatation-like follicle.
FIG. 3 is a graph showing the result of plateau catechol-improved PCOS model mouse endometrium morphology, in which graph A shows the change of the normal mouse estrus cycle, graph B shows the change of the PCOS model mouse estrus cycle, and graph C shows the change of the plateau catechol-treated mouse estrus cycle. Wherein P, E, D/M represents prophase Estrus (promestrus), Estrus (Estrus), and postestrus/Estrus (Metastrus/Diestus), respectively.
FIG. 4 is a graph of the results of plateau catechol improvement in serum hyperandrogenism (T) in PCOS model mice. Data were corrected for Dunne t post-hoc test using one-way ANOVA with p < 0.05.
Detailed Description
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention. Test methods in which specific conditions are not specified in the following examples are generally carried out under conventional conditions or under conditions recommended by the respective manufacturers. When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, and materials used in the examples, any methods, devices, and materials similar or equivalent to those described in the examples may be used in the practice of the invention in addition to the specific methods, devices, and materials used in the examples, in keeping with the knowledge of one skilled in the art and with the description of the invention.
Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed herein all employ techniques conventional in the art of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related arts.
One embodiment of the invention is an application of the homoprotocatechuic acid in preparing a medicament for treating polycystic ovary syndrome.
Alternatively, plateau catechins are used as the sole active ingredient or one of the active ingredients of a medicament for the treatment of polycystic ovary syndrome.
The new application of the plateau catechin in pharmacy is specifically the application of the plateau catechin in preparing medicines for improving the symptoms of polycystic ovary syndrome diseases and treating polycystic ovary syndrome ovarian lesions and systemic hormone disorder.
In the medicine for treating polycystic ovary syndrome, plateau catechin is a flavonol secondary metabolite monomer, and the medicine concentration of the plateau catechin is 80 mu mol/L. The medicine is dissolved in the daily drinking water of experimental animals and is orally taken.
Optionally, the medicine for treating polycystic ovary syndrome further comprises a pharmaceutically acceptable carrier or an auxiliary material.
By "pharmaceutically acceptable" is meant that the molecular entities and compositions do not produce adverse, allergic, or other untoward reactions when properly administered to an animal or human.
The "pharmaceutically acceptable carrier or adjuvant" should be compatible with the active ingredient, i.e., capable of being blended therewith without substantially diminishing the effectiveness of the drug under ordinary circumstances. Specific examples of some substances that can serve as pharmaceutically acceptable carriers or adjuvants are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium methylcellulose, ethylcellulose and methylcellulose; powdered gum tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cocoa butter; polyhydric alcohols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as Tween; wetting agents, such as sodium lauryl sulfate; a colorant; a flavoring agent; tabletting agents, stabilizers; an antioxidant; a preservative; pyrogen-free water; isotonic saline solution; and phosphate buffer, and the like. These materials are used as needed to aid in the stability of the formulation or to aid in the enhancement of the activity or its bioavailability or to produce an acceptable mouthfeel or odor upon oral administration.
In the present invention, unless otherwise specified, the pharmaceutical form is not particularly limited, and for example, the pharmaceutical form for preventing and treating sepsis damage is selected from tablets, capsules, granules, suspensions, emulsions, solutions, syrups, sprays, or injections.
One embodiment of the invention provides a medicine for treating polycystic ovary syndrome, which contains plateau catechin. Provides the application of plateau catechin in preparing products containing any one or more of the following functions: (1) increasing the number of corpus luteum in the ovary of the subject; (2) treating endometrial tissue damage; (3) relieving the disturbance of the estrous cycle of the affected subject; (4) reducing serum androgen levels in the subject.
The increase of the corpus luteum quantity in the ovary of the subject means that the product can enable the corpus luteum quantity in the ovary of the subject to approach or reach a healthy level. For example, the product can increase the number of corpus luteum in ovary of subject to be treated to 80%, 85%, 90%, 95%, 100% of the number of corpus luteum in healthy ovary based on the number of corpus luteum in ovary of subject to be treated.
The treatment of endometrial tissue damage means that the product can enable the morphology of endometrial tissue of an affected object to approach or reach a healthy endometrial level. The endometrial tissue morphology includes endometrial thickness, number of gland openings, number of glands, and the like. For example, the product can increase endometrial thickness, number of gland openings, and number of glands of endometrial tissue to 80%, 85%, 90%, 95%, and 100% of normal endometrial tissue based on healthy endometrial tissue.
The alleviation of the estrus cycle disorder of the acting object means that the product can make the estrus disorder degree of the acting object approach or reach the estrus cycle of a healthy object. For example, the product may reduce the estrus disturbance in the subject to be treated to no more than 120%, 110%, 100% of the estrus disturbance in healthy subjects, based on healthy subjects.
By reducing the serum androgen level of a subject, it is meant that the product is capable of bringing the serum androgen level of the subject to a healthy level. For example, the product may lower the serum androgen level in a subject to be affected to no more than 1.1-fold the serum androgen level in a healthy subject, based on the serum androgen level in a healthy subject.
Plateau catechins are used as the only active ingredient or one of the active ingredients of the medicine for treating polycystic ovary syndrome.
In the medicine for treating polycystic ovary syndrome, plateau catechin is a flavonol secondary metabolite monomer, and the medicine concentration of the plateau catechin is 80 mu mol/L.
Optionally, the medicine for treating polycystic ovary syndrome further comprises a pharmaceutically acceptable carrier or an auxiliary material.
The subject may be a mammal. The mammal is preferably a rodent, artiodactyla, perissodactyla, lagomorpha, primate, or the like. The primate is preferably a monkey, ape or human.
Example 1: the plateau catechin can relieve the disease symptoms of polycystic ovary syndrome mice, relieve hormone disorder and improve ovarian lesion
1 materials of the experiment
1.1 Experimental animals: female C57BL/6J mice, weighing 20-22 g, were purchased from Cheng Biotech, Inc., Guangzhou, for 8-10 weeks.
2 method of experiment
2.1 PCOS animal model construction: dehydroepiandrosterone (DHEA) is injected subcutaneously at 60mg/Kg/d of neck and back, and the medicine is molded continuously for 21 days.
2.2 experimental animal groups: randomly dividing 3-week-old C57BL/6 female mice into 3 groups, namely a Control group (Control group), a POCS animal model group (PCOS group), and a plateau catechol treatment group (PCOS + DOPAC group); plateau catechol treatment group mice treatment: preparing plateau catechol therapeutic solution: 2.688mg plateau catechol is dissolved in 200mL pure drinking water (the concentration is 80 mu mol/L), and the solution is drunk by PCOS + DOPAC group mice, after drinking for 1 week, PCOS modeling is carried out on the PCOS + DOPAC group mice and the PCOS group mice according to the method of the step 2.1, during the modeling, the PCOS + DOPAC group mice drink plateau catechol therapeutic solution until the model construction is completed, the Control group mice and the PCOS group mice drink common pure water, the PCOS + DOPAC group mice drink DOPAC therapeutic solution to completely replace the pure water, and the DOPAC dosage used by the mice is not completely fixed. Generally, mice will drink from 4-5 milliliters of water a day.
2.3 mouse vaginal secretion smear and estrus cycle observations
Mice in the group started on day 14 according to the 2.1 modeling protocol, and were subjected to vaginal secretion smear and estrous cycle observation: collecting mouse vaginal secretion smears, fixing, then carrying out crystal violet staining, and continuously observing for 7 days to judge the change of the estrous cycle rule of the mouse: namely, the non-keratinized epithelial cells are mainly used in the prophase of estrus, and the keratinized epithelial cells are mainly used in the estrus; the ratio of 3 cells including leucocytes, keratinized epithelial cells and non-keratinized epithelial cells is equal in the anaphase of estrus; the estrus is mainly white blood cells.
2.4 detection of morphological changes in ovarian and uterine tissue
After the molding scheme of 2.1 is finished, taking a mouse ovary tissue, respectively placing a fresh mouse ovary and a fresh uterus in 4% paraformaldehyde for fixation for 24 hours, and setting a program on an automatic dehydration instrument for dehydration; embedding; the thickness of the paraffin sections was 3 μm. Then HE staining: placing the slices in an oven at 60 ℃ for 1 h; dewaxing twice in xylene for 10 min; placing in gradient ethanol solution for removing xylene, anhydrous ethanol I for 5min, anhydrous ethanol II for 5min, 95% ethanol for 3min, and 70% ethanol for 3 min; staining with hematoxylin solution for 5min, and washing with water for 1 min; differentiating with 1% ethanol solution of hydrochloric acid, and washing with water for 1 min; anti-blue with 0.2% ammonia water for 1 min; staining with 1% eosin solution for 30 s; dehydrating with 95% ethanol for 30s, and extracting with anhydrous ethanol for 1min and 1 min; xylene was transparent twice, 1min each time. And sealing the tablets by using neutral gum, observing and photographing by using an optical microscope, observing the change of endometrium, and counting the number of cystic follicles and corpus luteum in the ovary.
2.5 detection of androgen levels in the serum of mice by enzyme-linked immunosorbent assay (ELISA): ELISA kits were purchased from Bioswamp, China and used according to the instructions.
3 results of the experiment
3.1 As shown in FIG. 1, the estrus cycle of the mice in the PCOS group is irregularly changed, and the estrus cycle of the mice in the PCOS + DOPAC group is obviously improved.
3.2 As shown in FIG. 2, a typical PCOS pattern of a post-dilated cystic follicle in the ovary of mice in the PCOS group is characterized and the number of corpus luteum is reduced; the ovary dilatation saccular structure of mice in the PCOS + DOPAC group is obviously improved, and the number of the dilatation-like follicles is obviously reduced (p is 0.09).
3.3 As shown in FIG. 3: the endometrium of the POCS group mouse is obviously thinned, the basal layer basically disappears, and the gland opening is obviously reduced; the uterine structure of the mice in the PCOS + DOPAC group is recovered, and the number of glands is obviously increased.
3.4 as shown in FIG. 4: compared with PCOS group mice, the serum androgen level of the PCOS + DOPAC group is obviously reduced, which shows that plateau catechol can obviously improve the PCOS high androgen symptom (p is less than 0.05).
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (10)
1. Use of plateau catechin in preparing medicine for treating polycystic ovary syndrome (HO)2C6H3CH2CO2H, CAS:102-32-9, the structural formula is shown as the formula (I):
2. the use according to claim 1, characterized in that plateau catechins are used as the sole active principle or one of the active principles of a medicament for the treatment of polycystic ovary syndrome.
3. The use according to claim 1, wherein the drug for treating polycystic ovary syndrome comprises high protocatechuic acid as a secondary metabolite monomer of flavonols, and the drug concentration of high protocatechuic acid is 80 μmol/L.
4. The use of claim 1, wherein the medicament for the treatment of polycystic ovary syndrome further comprises a pharmaceutically acceptable carrier or adjuvant.
5. The use according to claim 1, wherein the pharmaceutical form for the treatment of polycystic ovary syndrome is selected from the group consisting of tablets, capsules, granules, suspensions, emulsions, solutions, syrups, sprays, or injections.
6. The medicine for treating polycystic ovary syndrome is characterized by comprising plateau catechin.
7. The drug for treating polycystic ovary syndrome according to claim 6, wherein plateau catechin is used as the only active ingredient or one of the active ingredients of the drug for treating polycystic ovary syndrome.
8. The drug for treating polycystic ovary syndrome according to claim 6, wherein the drug for treating polycystic ovary syndrome comprises plateau catechin which is a secondary metabolite monomer of flavonols, and the drug concentration of plateau catechin is 80 μmol/L.
9. The medicament for treating polycystic ovary syndrome according to claim 6, wherein the medicament further comprises a pharmaceutically acceptable carrier or adjuvant.
10. Use of plateau catechins in the manufacture of a product comprising any one or more of the following effects: (1) increasing the number of corpus luteum in the ovary of the subject; (2) treating endometrial tissue damage; (3) relieving the disturbance of the estrous cycle of the affected subject; (4) reducing serum androgen levels in the subject.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210076827.5A CN114452274A (en) | 2022-01-21 | 2022-01-21 | Application of plateau catechuic acid in preparing medicine for treating polycystic ovary syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210076827.5A CN114452274A (en) | 2022-01-21 | 2022-01-21 | Application of plateau catechuic acid in preparing medicine for treating polycystic ovary syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114452274A true CN114452274A (en) | 2022-05-10 |
Family
ID=81410717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210076827.5A Pending CN114452274A (en) | 2022-01-21 | 2022-01-21 | Application of plateau catechuic acid in preparing medicine for treating polycystic ovary syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114452274A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417521A (en) * | 2012-05-15 | 2013-12-04 | 北京京朋汇药业研究发展有限公司 | Application of 3,4-Dihydroxyphenylacetic acid in preparing antitumor drug |
-
2022
- 2022-01-21 CN CN202210076827.5A patent/CN114452274A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417521A (en) * | 2012-05-15 | 2013-12-04 | 北京京朋汇药业研究发展有限公司 | Application of 3,4-Dihydroxyphenylacetic acid in preparing antitumor drug |
Non-Patent Citations (1)
| Title |
|---|
| RUPAVATH CHANDRASHEKHAR1等: "Protective and therapeutic effect of protocatechuic acid in assessment of letrozoleinduced polycystic ovary syndrome in rats", 《ASIAN PACIFIC JOURNAL OF REPRODUCTION》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116196323B (en) | Application of typha saponin in preparing medicament for reducing uric acid and/or treating kidney injury | |
| WO2019134159A1 (en) | Rectal mucosal administration preparation of pulsatilla chinensis (bge.) regel saponin b4 and preparation method therefor | |
| CN109381473B (en) | Application of baicalin in preparation of medicine for preventing gestational diabetes mellitus fetal neural tube malformation | |
| EA001325B1 (en) | Methods ot treating or preventing interstitial cystitis | |
| CN114452274A (en) | Application of plateau catechuic acid in preparing medicine for treating polycystic ovary syndrome | |
| CN103356630B (en) | Containing pentoxifylline and the pharmaceutical composition of prucalopride and medical usage thereof | |
| CN112402428B (en) | Application of remazolin in preparation of medicine for treating postoperative hyperalgesia induced by opioid | |
| CN114796195A (en) | Application of icaritin in preparation of pharmaceutical composition for protecting acute lung injury induced by lipopolysaccharide | |
| CN102836152B (en) | Application of physalin B in preparation of medicine for curing and/or preventing schistosomiasis | |
| CN106075001A (en) | Water-soluable gel containing Sanguis Draxonis polyphenol and the purposes on treatment cervical erosion medicine thereof | |
| CN111467327A (en) | Application of zingiberone A in preparation of colitis prevention and treatment medicines | |
| CN114288301B (en) | Application of DTQ in preparation of medicines for treating acute myocardial infarction and related products | |
| CN117982486A (en) | Application of wogonin derivative V8 in preparation of medicines for preventing and treating liver fat metabolic disorder related diseases | |
| CN114053283B (en) | Application of 3 beta, 23-O-isopropylidene hydroxyl betulinic acid in preparing medicine for treating non-alcoholic steatohepatitis | |
| CN114681469B (en) | Application of hydroxy salicylic acid in preparation of medicine for treating premature ovarian failure | |
| CN116983315B (en) | Application of 12-ketolithocholic acid in preparation of medicines for preventing and treating ulcerative colitis | |
| WO2022242769A1 (en) | Use of pyridone derivative containing heteroatom cyclobutane substituent | |
| CN110327354B (en) | Application of diosgenin in treatment and prevention of psoriasis | |
| CN114159435B (en) | Application of Fuziling in preparing medicine for treating arthritis | |
| CN114832031B (en) | Application of red sage root extract, its preparation method and its medicinal composition | |
| RU2803967C1 (en) | Medical use of anemozide b4 in treatment of ulcers in oral cavity | |
| WO2023068778A1 (en) | Composition for prevention and treatment of female menopausal diseases comprising phytogen as active ingredient | |
| DK2253228T3 (en) | Composition for controlling and enhancing female and male gametogenesis | |
| CN115887439A (en) | Application of compound in preparation of polycystic ovarian syndrome ovarian protection medicine | |
| CN114042062A (en) | Application of formononetin in preparation of medicines for preventing and treating sepsis injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220510 |
|
| RJ01 | Rejection of invention patent application after publication |